Sure, though (and this is usually reflected in research that it includes it now), lifespan alone for alternatives isn't the only or necessarily most important piece of comparative information; relative risks of other conditions even if they are non-fatal and other quality-of-life concerns are important, too. For aggregate purposes when we aren't comparing path risks but looking at overall status, the patallel is merely statistics on the incidence of various conditions and effects with quality-of-life impacts, which is currently done separately from life expectancy.